Business

May 8, 2014

BioCryst shares fall after reporting potential setback for peramivir

BioCryst Pharmaceuticals stock fell 14 percent after the company reported another potential setback for its intravenous flu treatment peramivir.

Related content

Comments

Videos

Editor's Choice Videos